{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:10:54Z","timestamp":1774620654231,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.trre.2025.100941","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:29:37Z","timestamp":1751916577000},"page":"100941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging strategies in the transplantation of HCV-infected pancreases to uninfected recipients: A narrative review"],"prefix":"10.1016","volume":"39","author":[{"given":"Adam J.","family":"Bush","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn A.E.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2025.100941_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5500\/wjt.v9.i4.81","article-title":"Pancreatic transplantation: brief review of the current evidence","volume":"9","author":"Aref","year":"2019","journal-title":"World J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajt.2024.01.013","article-title":"OPTN\/SRTR 2022 annual data report: pancreas","volume":"24","author":"Kandaswamy","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ajt.16979","article-title":"OPTN\/SRTR 2020 Annual Data Report: Pancreas","volume":"22","author":"Kandaswamy","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0020","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2025.100941_bb0025","series-title":"Guidance on Explaining Risk Related to Use of U.S. PHS Increased Risk Donor Organs When Considering Organ Offers [Internet]","author":"Wholly","year":"2017"},{"key":"10.1016\/j.trre.2025.100941_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2021.100677","article-title":"Hepatitis C virus and kidney transplantation: recent trends and paradigm shifts","volume":"36","author":"El Helou","year":"2022","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2025.100941_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1034\/j.1399-0012.2002.01116.x","article-title":"Impact of hepatitis C virus status in pancreas transplantation: a case controlled study","volume":"16","author":"Honaker","year":"2002","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2025.100941_bb0040","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3748\/wjg.v22.i4.1650","article-title":"Hepatitis C in non-hepatic solid organ transplant candidates and recipients: a new horizon","volume":"22","author":"Belga","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.trre.2025.100941_bb0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.kint.2021.06.034","article-title":"A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients","volume":"100","author":"Daloul","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2025.100941_bb0050","article-title":"Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: An updated meta-analysis. Ho W","volume":"9","author":"Wei","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2025.100941_bb0055","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/lt.25424","article-title":"Improved graft survival after liver transplantation for recipients with hepatitis C virus in the direct-acting antiviral era","volume":"25","author":"Cotter","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2025.100941_bb0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5500\/wjt.v8.i4.84","article-title":"Hepatitis C and renal transplantation in era of new antiviral agents","volume":"8","author":"Salvadori","year":"2018","journal-title":"World J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0065","series-title":"Sofosbuvir\u2013velpatasvir\u2013voxilaprevir for treating chronic hepatitis C: Technology appraisal guidance: [Internet]","year":"2018"},{"key":"10.1016\/j.trre.2025.100941_bb0070","series-title":"Glecaprevir\u2013pibrentasvir for treating chronic hepatitis C: Technology appraisal guidance [Internet]","year":"2018"},{"key":"10.1016\/j.trre.2025.100941_bb0075","author":"American Association for the Study of Liver Diseases. AASLD-IDSA"},{"key":"10.1016\/j.trre.2025.100941_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.11.001","article-title":"Hepatitis C standards of care: a review of good practices since the advent of direct-acting antiviral therapy","volume":"45","author":"Lazarus","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.trre.2025.100941_bb0085","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12882-020-02114-y","article-title":"Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation","volume":"21","author":"Edwards","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2025.100941_bb0090","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/apt.16508","article-title":"Systematic review: hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation","volume":"54","author":"Raasikh","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.trre.2025.100941_bb0095","first-page":"85","article-title":"Hepatitis C virus treatment and solid organ transplantation","volume":"18","author":"Patnaik","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.trre.2025.100941_bb0100","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/ajt.16465","article-title":"Pancreas transplantation from hepatitis C viremic donors to uninfected recipients","volume":"21","author":"Lonze","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10277","article-title":"Kidney transplantation from hepatitis-C viraemic donors:considerations for practice in the United Kingdom","volume":"35","author":"Doherty","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100941_bb0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-Centre, open-label study","volume":"5","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.trre.2025.100941_bb0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nm.2581","article-title":"Identification of the Niemann-pick C1\u2013like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor","volume":"18","author":"Sainz","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.trre.2025.100941_bb0125","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2025.100941_bb0130","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2025.100941_bb0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5414\/CN108858","article-title":"KDPI score is a strong predictor of future graft function: Moderate KDPI (35\u201385) and high KDPI (> 85) grafts yield similar graft function and survival","volume":"86","author":"Gupta","year":"2016","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2025.100941_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/zxab207","article-title":"Access to direct-acting antivirals for hepatitis C\u2013negative transplant recipients receiving organs from hepatitis C\u2013viremic donors","volume":"79","author":"Bova","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.trre.2025.100941_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/sdi.12767","article-title":"Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus-infected donors into hepatitis C virus-negative patients","volume":"32","author":"Goldberg","year":"2019","journal-title":"Semin Dial"},{"key":"10.1016\/j.trre.2025.100941_bb0150","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000004022","article-title":"Ultrashort duration prophylaxis for hepatitis C donor positive to recipient negative simultaneous kidney\/pancreas transplants","volume":"106","author":"Gupta","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100941_bb0155","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients","volume":"20","author":"Gupta","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12876-022-02107-1","article-title":"Hepatitis C positive organ transplantation to negative recipients at a multiorgan Canadian transplant Centre: ready for prime time","volume":"22","author":"Alghamdi","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.trre.2025.100941_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-254331","article-title":"Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures","volume":"16","author":"Schulz","year":"2023","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.trre.2025.100941_bb0170","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.trre.2025.100941_bb0175","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ajt.2023.10.006","article-title":"Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: results from the HCV-TARGET study","volume":"24","author":"Aleyadeh","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ajt.2024.09.006","article-title":"Multivisceral transplantation utilizing hepatitis C virus\u2013viremic donors for hepatitis C virus\u2013negative recipients","volume":"25","author":"Addison","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.trre.2025.100941_bb0190","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2025.100941_bb0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of Hepatitis C\u2013infected kidneys into uninfected recipients: A Single-Group Trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2025.100941_bb0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus\u2013infected donors to noninfected recipients: An open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2025.100941_bb0205","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1681\/ASN.2020050686","article-title":"Multicenter study to transplant Hepatitis C\u2013infected kidneys (MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection","volume":"31","author":"Sise","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2025.100941_bb0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M20-1468","article-title":"Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C\u2013Viremic Donors to Hepatitis C\u2013Negative Recipients: An Open-Label Nonrandomized Study","volume":"174","author":"Durand","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2025.100941_bb0215","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/hep.31551","article-title":"Prospective Multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-Viremic donors","volume":"73","author":"Terrault","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.trre.2025.100941_bb0220","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C\u2013infected donors to hepatitis C\u2013negative recipients: single center experience","volume":"19","author":"Molnar","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100941_bb0225","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13146","article-title":"Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients","volume":"21","author":"Friebus-Kardash","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100941_bb0230","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1111\/tri.14152","article-title":"Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus","volume":"34","author":"Yuan","year":"2021","journal-title":"Transpl Int"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:55:43Z","timestamp":1763751343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X25000412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0955470X25000412"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2025.100941","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging strategies in the transplantation of HCV-infected pancreases to uninfected recipients: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2025.100941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100941"}}